Cargando…
A new noninvasive technique for estimating hepatic triglyceride: will liver biopsy become redundant in diagnosing non-alcoholic fatty liver disease?
Obesity and metabolic syndrome are healthcare problems that continue to rise in frequency worldwide. Both phenotypes are a strong predictor for development of liver steatosis in the context of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis. Ultrasound may detect steatosis, but it...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4148002/ https://www.ncbi.nlm.nih.gov/pubmed/25164119 http://dx.doi.org/10.1186/s12916-014-0152-z |
_version_ | 1782332545971519488 |
---|---|
author | Betzel, Bark Drenth, Joost PH |
author_facet | Betzel, Bark Drenth, Joost PH |
author_sort | Betzel, Bark |
collection | PubMed |
description | Obesity and metabolic syndrome are healthcare problems that continue to rise in frequency worldwide. Both phenotypes are a strong predictor for development of liver steatosis in the context of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis. Ultrasound may detect steatosis, but its sensitivity is limited and liver biopsy is still considered to be the gold standard. Less invasive techniques that accurately quantify liver steatosis are warranted. Jiménez-Agüero and colleagues propose that multi-echo magnetic resonance imaging might be such a diagnostic tool. They validated multi-echo magnetic resonance imaging with measured hepatic triglyceride concentration. Their results show that this innovative technique measures the grade of steatosis in different clinical situations. Therefore, multi-echo magnetic resonance imaging might be considered for monitoring liver steatosis as an intermediate endpoint. Wide clinical applicability is limited though, as it does not allow differentiation between non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. |
format | Online Article Text |
id | pubmed-4148002 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-41480022014-08-29 A new noninvasive technique for estimating hepatic triglyceride: will liver biopsy become redundant in diagnosing non-alcoholic fatty liver disease? Betzel, Bark Drenth, Joost PH BMC Med Commentary Obesity and metabolic syndrome are healthcare problems that continue to rise in frequency worldwide. Both phenotypes are a strong predictor for development of liver steatosis in the context of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis. Ultrasound may detect steatosis, but its sensitivity is limited and liver biopsy is still considered to be the gold standard. Less invasive techniques that accurately quantify liver steatosis are warranted. Jiménez-Agüero and colleagues propose that multi-echo magnetic resonance imaging might be such a diagnostic tool. They validated multi-echo magnetic resonance imaging with measured hepatic triglyceride concentration. Their results show that this innovative technique measures the grade of steatosis in different clinical situations. Therefore, multi-echo magnetic resonance imaging might be considered for monitoring liver steatosis as an intermediate endpoint. Wide clinical applicability is limited though, as it does not allow differentiation between non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. BioMed Central 2014-08-26 /pmc/articles/PMC4148002/ /pubmed/25164119 http://dx.doi.org/10.1186/s12916-014-0152-z Text en © Betzel and Drenth; licensee BioMed Central Ltd. 2014 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Commentary Betzel, Bark Drenth, Joost PH A new noninvasive technique for estimating hepatic triglyceride: will liver biopsy become redundant in diagnosing non-alcoholic fatty liver disease? |
title | A new noninvasive technique for estimating hepatic triglyceride: will liver biopsy become redundant in diagnosing non-alcoholic fatty liver disease? |
title_full | A new noninvasive technique for estimating hepatic triglyceride: will liver biopsy become redundant in diagnosing non-alcoholic fatty liver disease? |
title_fullStr | A new noninvasive technique for estimating hepatic triglyceride: will liver biopsy become redundant in diagnosing non-alcoholic fatty liver disease? |
title_full_unstemmed | A new noninvasive technique for estimating hepatic triglyceride: will liver biopsy become redundant in diagnosing non-alcoholic fatty liver disease? |
title_short | A new noninvasive technique for estimating hepatic triglyceride: will liver biopsy become redundant in diagnosing non-alcoholic fatty liver disease? |
title_sort | new noninvasive technique for estimating hepatic triglyceride: will liver biopsy become redundant in diagnosing non-alcoholic fatty liver disease? |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4148002/ https://www.ncbi.nlm.nih.gov/pubmed/25164119 http://dx.doi.org/10.1186/s12916-014-0152-z |
work_keys_str_mv | AT betzelbark anewnoninvasivetechniqueforestimatinghepatictriglyceridewillliverbiopsybecomeredundantindiagnosingnonalcoholicfattyliverdisease AT drenthjoostph anewnoninvasivetechniqueforestimatinghepatictriglyceridewillliverbiopsybecomeredundantindiagnosingnonalcoholicfattyliverdisease AT betzelbark newnoninvasivetechniqueforestimatinghepatictriglyceridewillliverbiopsybecomeredundantindiagnosingnonalcoholicfattyliverdisease AT drenthjoostph newnoninvasivetechniqueforestimatinghepatictriglyceridewillliverbiopsybecomeredundantindiagnosingnonalcoholicfattyliverdisease |